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Abstract  
AIM: This study aimed to detect the most common HFE gene mutations (C282Y, H63D, and S56C) 
in Egyptian beta thalassemia major patients and its relation to their iron status.  
SUBJECTS AND METHODS: The study included 50 beta thalassemia major patients and 30 age 
and sex matched healthy persons as a control group. Serum ferritin, serum iron and TIBC level 
were measured. Detection of the three HFE gene mutations (C282Y, H63D and S65C) was done 
by PCR-RFLP analysis. Confirmation of positive cases for the mutations was done by sequencing.  
RESULTS: Neither homozygote nor carrier status for the C282Y or S65C alleles was found. The 
H63D heterozygous state was detected in 5/50 (10%) thalassemic patients and in 1/30 (3.3%) 
controls with no statistically significant difference between patients and control groups (p = 0.22). 
Significantly higher levels of the serum ferritin and serum iron in patients with this mutation (p = 
001).  
CONCLUSION: Our results suggest that there is an association between H63D mutation and the 
severity of iron overload in thalassemic patients. 
 
 
 
 
 
 
 
Introduction 
 
Thalassemias are a group of inherited 
disorders resulting from reduced rate of globin 
synthesis. This insufficiency prompts imbalanced 
globin chain synthesis, decreased the production of 
hemoglobin and destruction of the red cells or their 
precursors from the impacts of the globin subunits 
which are delivered in relative abundance (Fawdry, 
1944 [1]). 
The clinical picture of β-thalassemia is caused 
by anemia, blood transfusion and increased body iron. 
Transfusion therapy has fundamentally expanded the 
survival of patients with β thalassemia. However, both 
repeated transfusions and increased gut iron 
absorption have led to iron overload and an increment 
in the complications caused by increased total body 
iron (Borgna-Pignatti et al., 2004 [2]).  
Hereditary hemochromatosis (HH) is a 
genetic disorder characterized by iron overload 
resulting in multiorgan damage. The gene underlying 
this disorder has been identified as the HFE gene. 
The HFE gene has an important role in iron 
homeostasis by regulating the absorption of iron. HFE 
gene mutations are currently known as a cause of 
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increased iron absorption, iron overload and HH 
(Dhillon et al., 2012 [3]).  
Among the most frequently encountered 
mutations in HH are three missense mutations (SNPs) 
in HFE gene with an autosomal recessive pattern. The 
most common is a mutation within exon 4 of the HFE 
gene, resulting in an amino acid change at position 
282 from cysteine to tyrosine (C282Y), this mutation 
was found to be responsible for 60% of HH cases in 
Mediterranean populations .Another mutation is H63D 
which results in a C-G transition at nucleotide 187 of 
exon 2 of the HFE gene leading to a histidine to 
aspartic acid substitution. 
Iron overload is most pronounced when this 
allele is combined with C282Y allele (C282Y/H63D).  
The third HFE gene mutation is a 193A→T 
substitution in exon 2 with a resulting serine to 
cysteine substitution in amino acid position 65 (S65C) 
(Oliveira et al., 2006 [4]). 
Many studies have shown that beta-
thalassemia patients having HFE mutations are more 
likely to develop iron overload that may necessitate 
early iron chelation even in the heterozygous state 
(Sharma et al.,2005 [5]). Different methods can be 
used to genotype The HFE gene; these include RFLP 
(restriction fragment length polymorphism), DNA 
sequencing and the improved real-time PCR assay 
(Moyséset al., 2008 [6]). 
This study aimed to detect the most common 
HFE gene mutations (C282Y, H63D, and S56C) in 
Egyptian beta- thalassemia major patients and their 
relation to patients iron status. 
 
 
Subjects and Methods 
 
Patients with β thalassemia major (26 males 
and 24 females) and 30 age and sex matched 
controls were included in this study. The selected 
pediatric patients were referred from the Hematology 
Outpatient Clinic, Abou El Riche New Children 
Hospital, Cairo University to Human Genetics 
Department in the National Research Center, Cairo, 
Egypt. 
This study has been approved by the clinical 
pathology division Cairo University ethics committee 
and has been performed according to the ethical 
standards set down in the 1964 Declaration of 
Helsinki and its later corrections. 
Blood samples (10 ml) were collected from 
patients and controls. Screening for 
hemoglobinopathies was carried out by hemoglobin 
electrophoresis (Helena Laboratories, Beaumont, TX, 
USA), ferritin level assay was carried out by EIA 
(enzyme immunoassay), and iron and TIBC were 
assessed by automated analyzer (Olympus AU400). 
Hematologic values and red cell indices were 
obtained (ADVIA 120 Hematology System). 
As for transferrin saturation, it was calculated 
based on the equation: serum iron/TIBC × 100.  
 
Molecular studies 
Genomic DNA was extracted from peripheral 
leukocytes by the phenol-chloroform method. The 
Primer sequences, PCR product lengths, restriction 
endonucleases and restriction patterns for the H63D 
and S65C and C282Y genetic variants are shown in 
Table 1. 
Table 1: Primer sequences, PCR product lengths, restriction 
endonucleases and restriction patterns for the analyzed 
genetic variants 
Digested 
fragments 
length (bp)  
Restrictio
n enzyme 
Product 
length 
(bp) 
Reverse primer Forward primer Mutatio
n 
Not cut 
Not cut 
110, 290 
and 400  
BclI 
HinfI 
SnabI 
208 
208 
400 
5'GCCACATCTGGCTTGAAATT3' 
5'GCCACATCTGGCTTGAAATT3 
5'CTCAGGCACTCCTCTCAACC3' 
5'ACATGGTTAAGGCCTGTTGC3' 
5'ACATGGTTAAGGCCTGTTGC3 
5'TGGCAAGGGTAAACAGATCC3' 
H63D 
S65C 
C282Y 
 
 
The digestion products of the three mutations 
were analyzed on 3.0% agarose gel stained with 
ethidium bromide (Fig. 1a, b, c). 
a)  
b)  
c)  
Figure 1: The digestion products of the three mutations were 
analyzed on 3.0% agarose gel stained with ethidium bromide 
 
DNA sequencing 
DNA Sequencing was done for confirmation 
of the positive cases for mutations. Purification of 
PCR products to remove dNTPs and primers was 
performed using QIAquick PCR purification kit (Cat 
no. 28104). Cycle sequence PCR was carried out 
using Big Dye R Terminator kit (Cat no. 4336917-
USA). Cycle sequencing PCR was carried out on 
Perkin-Elmer thermal cycler (Applied Biosystem 2720, 
Singapore) using the following condition: Denaturation 
at 96°C for 1 min followed by 25 cycles of 
denaturation at 96°C for 10 sec, annealing at 56°C for 
5 sec, and elongation at 60°C for 4 min. The samples 
were injected into automatic sequencer and data were 
analyzed using ABI Prism DNA sequencing analysis 
software. 
As regards the H63D mutation, the presence 
of overlapping G and C peaks indicate the normal and 
Basic Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  228                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
mutant sequence of H63D mutation (Fig. 2a) whereas 
negative cases showed only C peak (Fig. 2b). 
 
a) 
 
b) 
 
Figure 2: The presence of overlapping G and C peaks indicate 
normal and mutant sequence of H63D mutation (a) whereas 
negative cases showed only C peak (b) 
 
Statistical analysis 
Data was analyzed using IBM advanced 
SPSS statistical package version 20 (SPSS Inc., 
Chicago, IL). Numerical data were expressed as a 
mean and standard deviation. Qualitative data were 
expressed as frequency and percentage.  
Data were analyzed by the chi-square test for 
multiple independent samples to identify the 
relationship between the mutations and the groups 
studied. Fisher’s exact test was used to compare 
results between the two groups. A P value < 0.05 was 
considered significant 
 
 
Results 
 
The clinical and laboratory data of the studied 
patients are shown in Table 2 
In the current study, all thalassemia major 
patients had elevated serum ferritin level, (10%) of 
patients had serum ferritin level < 1000 ng/ml, (30%) 
had serum ferritin between 1000 to 2500 ng/ml, while 
(60%) had values above 2500 ng/ml.  
Transferrin saturation was above 50% in 
48/50 (96%), only two cases (4%) had transferrin 
saturation below 50%. 
 
Table 2: Clinical and laboratory data of the studied patients 
 
 
 
Minimum 
 
Maximum 
 
Mean ± Std deviation 
Age (year) 11 40 27.2 ± 7 
Age at onset (month) 2 36 11.1 ± 9.5 
Frequency of blood 
transfusion/year 
8 24 14.8 ± 6.3 
Hb level (g/dl) 5.6 10 7.8 ± 1.2 
Ferritin (ng/ml) 723 7655 3487.3 ± 1886.1 
Serum iron (ug/dl) 50 348 205.3 ± 71.3 
TIBC (ng/ml) 180 400 273 ± 59.4 
Transferrin saturation% 20 106.6 75.1 ± 17.4 
Normal s. iron: - males 65-175 g/dL; Females 50-170 g/dL, TIBC: 20 to 150 ng/mL; 
ferritin: male: 12-300 ng/mL; female: 12-150 ng/mL, transferrin saturation: 20–50%.  
 
Genotyping of S65C and C282Y mutation 
The S65C and C282Y mutations were absent in all 
beta thalassemia major patients as well as in the 
control group. 
 
Genotyping of H63D mutation 
Allelic frequency of H63D mutation was found 
to be 10%, (5/50) in beta thalassemia major patients, 
heterozygous HD genotype, while the rest 90%, 
(45/50), showed no mutation HH genotype. None of 
the patients showed the HH homotype. 
As for control group only 1 individual (1/30), 
3.3% showed the heterotype HD for H63D 
genotyping. 
Analysis of genotypes of this mutation 
revealed that the frequency of HD genotype was 
higher among beta-thalassemia major patients (5 of 
50), 10% than healthy controls (1 of 30), 3.3%. There 
was no statistically significant difference in the 
frequency of HH, HD or DD genotypes between 
thalassemia patients and the control group (Table 3). 
Table 3: Distribution of H63D genotype and alleles between 
thalassemic patients and controls  
 Thalassemic patients 
( N = 50) 
Controls 
(N = 30) 
P value 
H63D  genotype 
H/H 
H/D 
D/D 
Number 
45 
5 
0 
Frequency 
90% 
10% 
0 
Number 
29 
1 
0 
Frequency 
96.7% 
3.3% 
0 
 
 
0.22 
H63D  alleles 
H 
D 
Number 
95 
5 
Frequency 
95% 
5% 
Number 
59 
1 
Frequency 
97.3% 
1.7% 
 
 
0.08 
 
There was a statistically significant difference 
on comparing beta-thalassemia patients with wild HH 
genotype and those carrying the heterozygous 
mutation HD genotype as regard the serum iron and 
serum ferritin levels which were significantly higher in 
HD genotype (Table 4). 
Table 4: Comparison between hematological and biochemical 
measurements in different H63D genotypes in beta-
thalassemia patients 
Parameter H/H 
mean ± SD 
N = 45 
H/D 
mean ± SD 
N = 5 
 
P value 
Ferritin (ng/ml)       3121.8 ± 1600 6778 ± 581 0.01** 
Serum iron (ug/dL)         194.6 ± 66.2 319.2 ± 58.2 0.01** 
TIBC (ng/ml) 265.4 ± 56.8 296.8 ± 55.3 0.07 
Transferrin saturation (%)   73.5 ± 17   83.2 ± 7.1 0.23 
*p < 0.05 = significant. 
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Discussion 
 
Iron overload is the main cause of significant 
morbidity and mortality in thalassemia. The 
progressive iron overload in beta-thalassemia major 
patients results from ineffective erythropoiesis 
increased absorption of iron by the gastrointestinal 
tract, defective physiologic excretion of excess iron, 
and essentially, multiple blood transfusions 
(Giardina and Grady 2008 [7]). 
Hereditary hemochromatosis is an autosomal 
recessive disease characterized by increased 
intestinal iron absorption and progressive iron 
overload (Jowkar et al., 2011 [8]). Mutations in the 
HFE gene, known to be significantly associated with 
hereditary hemochromatosis, were found to have a 
modifying effect on iron absorption in thalassemia 
patients (Camaschella et al., 2002 [9]). 
In this study, we have investigated the 
possible association between iron overload and three 
mutations in HFE gene (C282Y, H63D and S65C 
mutations) in beta thalassemia major patients. 
We found that all thalassemia major patients 
had elevated serum ferritin, where 5/50 (10%) of 
patients had serum ferritin level < 1000 ng/ml, 15/50 
(30%) had serum ferritin between 1000 to 2500 ng/ml, 
while 30/50 (60%) had values above 2500 ng/ml. 
The serum iron and TIBC levels in the present 
study were 205.3 ± 71.3 mg/dl and 273 ± 59.4 mg/dl 
respectively, iron chelation therapy was not equally 
efficacious in the cases as reflected by variable serum 
iron, TIBC, and serum ferritin. This could be explained 
by the fact that the clinical phenotype of homozygous 
beta-thalassemia may be altered when other genetic 
variants present outside the globin clusters are co-
inherited as well. These genetic modifiers influence 
mainly impact for the most part of the thalassemia 
complications (Galanello and Origa 2010 [10]).  
In this study, the three mutations in HFE gene 
(C282Y, H63D and S65C mutations) were screened in 
50 patients and our results have been compared with 
30 healthy individuals which were taken as a control 
group. 
The screening of C282Y and S65C mutations 
revealed that these mutations were not found in the 
thalassemia or control group. 
Our finding is concurrent with that of Karimi et 
al, (2004) who studied 203 normal adults and 154 
transfused patients affected with β-thalassemia in Iran 
and the two mutations were not present in both 
groups [11]. 
Also in agreement with our study, the C282Y 
mutation was not observed in another study done in 
Tunis on 50 beta thalassemia patients (Mellouli et al., 
2006 [12]).  
In another study done by Kaur et al, (2004), 
who studied Asian-African and Middle Eastern origins 
living in the USA, it was found that 2 out of 81 patients 
were positive for C282Y mutation while H63D 
mutation was not observed (Kaur and Andersen 2004) 
[13]. This finding confirms the rarity of C282Y 
mutation in the African populations. 
In the current study, H63D mutation was 
found in 5/50 thalassemia patients (10%) compared to 
1/30 in the control group (3.3%) with allele frequency 
0.5% in beta-thalassemia patients and (1.7%) in the 
control group. 
Another study in India revealed a higher 
frequency of H63D mutation, they studied 75 
thalassemia major patients in North India and reported 
that H63D mutation was observed in 12% patients 
compared to 8.6% in a control group of India [14]. 
In agreement with our results the allele 
frequencies in thalassemia patients in Brazil were 
0.29%, 13.70% and 0.60% for the C282Y, H63D and 
S65C mutation respectively [15]. 
In the present study, there was no statistically 
significant difference in the frequency of H63D 
mutation between β-thalassemic patients and the 
control group (p = 0.22). 
In close agreement with our results, previous 
studies in Tunis and India reported that there was no 
significant difference in the prevalence of HH, HD or 
DD genotypes between thalassemia patients and 
healthy controls (Kaur D and Andersen. 2004 [13]).  
However, the role of HFE gene mutations on 
developing iron overload was previously studied in 41 
beta-thalassaemia carriers in Egypt and it was found 
to be more common among beta-
thalassaemia carriers compared with normal controls 
(H63D, S65C, and C282Y allele frequencies were 
30.5%, 13.4% and 7.3% respectively in beta-
thalassaemia carriers and 10.0%, 2.5% and 0.0% 
respectively in the control group). This difference may 
be related to the limited sample size in both studies, in 
addition, the verification of the presence of mutation 
by sequencing in our study is more in favor for a lower 
frequency rate (Madani et al.,2011 [15]).  
  Interestingly, there was a significant 
difference between serum ferritin level and serum iron 
in beta-thalassemia patients with and without the 
H63D mutation (P = 0.001). We found that in the 
group with H63D mutation patients had serum ferritin 
above 2500 ng/ml (p < 0.05). 
These findings point to a possible association 
between H63D mutation and the severity of iron 
overload in thalassemic patients. 
A similar result was also described by Melis et 
al, (2002) [14], who suggested that the H63D mutation 
may have a modifying effect on iron absorption and 
that the inheritance of H63D mutation may aggravate 
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the beta-thalassemia trait even if present in 
heterozygous state (Melis et al., 2002) [14]. 
Also in agreement with our results Sharma et 
al, (2007) concluded that thalassemia intermedia 
patients with co-existent HFE mutation are more likely 
to develop iron overload and may need early iron 
chelation therapy [5]. 
  A different finding was observed in previous 
studies by Mellouli et al, (2006), who suggested that 
the inheritance of H63D mutation does not influence 
the severity of iron overload in beta-thalassemia 
patients (Mellouli et al., 2006) [12].  
Also, Garewal et al, (2005) suggested that the 
presence of H63D mutation does not increase body 
iron as measured by serum ferritin in beta thalassemia 
[16].  
Previous studies have yielded clashing 
results: some proposed iron overload may emerge 
from the association of the β-thalassemia with 
homozygosity or even heterozygosity for HFE 
mutations and others claimed that no relation exists 
between total body iron and HFE genotypes (López-
Escribano et al., 2012 [17]) 
The discrepancy between our results and the 
previous results has several explanations as the 
expression of HFE hemochromatosis is modified by 
genetic and acquired factors, for example, dietary 
habits, blood loss or donation, pregnancy, 
menopause, malabsorption (Sharma et al.,2007 [5]). 
As a second explanation, mutations in the 
HFE gene other than those tested in this study may 
be responsible for the iron overload and to higher 
serum ferritin. 
Our study suggests that somehow, HFE gene 
mutations could be involved in increasing iron storage 
possibly through interaction with other genetic 
determinants of β-thalassaemia. This can lead to iron 
overload with secondary tissue harm in multiple body 
organs creating most of morbidity and mortality in 
thalassemia patients. 
Therefore, this study supports the importance 
of screening of HFE gene mutations in thalassemia 
patients for detection of those having a higher 
likelihood of developing iron overload even when the 
mutation is present in the heterozygous state.  
This may enhance the quality of life in these 
patients by frequent follow-up for prior detection of 
iron overload and its complications and by applying 
more aggressive iron chelating protocols.  
Recommendations: This study should be 
expanded to include a larger number of patients as 
well as a control population. We recommend testing of 
patients with thalassemia “intermedia and minor" for 
the presence of HFE gene mutations and correlate its 
presence with the serum ferritin level. 
Also, we need testing for other HFE gene 
mutations or other genes involved in hereditary 
hemochromatosis in the iron-overloaded patients, who 
were negative for the C282Y, H63D and S65C 
mutations. 
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